{
  "paper_id": "PMC7667107",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667107/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Study flowchart.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/fda8c139d23a/gs-09-05-1813-f1.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/fda8c139d23a/gs-09-05-1813-f1.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/fda8c139d23a/gs-09-05-1813-f1.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/fda8c139d23a/gs-09-05-1813-f1.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/fda8c139d23a/gs-09-05-1813-f1.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC7667107/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/fda8c139d23a/gs-09-05-1813-f1.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "Global map of RAS mutation (A) and PAX8/PPARγ rearrangement (B) in FTC patients. Countries where the data are unavailable are shown in white. FTC, follicular thyroid carcinoma.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/a141e164bff6/gs-09-05-1813-f2.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/a141e164bff6/gs-09-05-1813-f2.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/a141e164bff6/gs-09-05-1813-f2.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/a141e164bff6/gs-09-05-1813-f2.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/a141e164bff6/gs-09-05-1813-f2.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC7667107/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/a141e164bff6/gs-09-05-1813-f2.jpg"
    }
  },
  "claims": [
    {
      "sentence": "We used the remaining 71 studies that included data of at least one genetic alteration in our final analysis (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2A show the worldwide frequency of RAS mutation.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Country/region\nNo. studies\nNRAS\nHRAS\nKRAS\nAny RAS\nPAX8/PPARγ\n\nNo. with a mutation/total no. [%]\n\n\n\nAsia\n\n\n\n\n\n\n\n\n   China\n1 (34)\n10/53 [19]\n4/53 [8]\n3/53 [3]\n17/53 [32]\n1/53 [2]\n\n\n   Japan\n10 (6,10,16,17,21-26)\n63/215 [29]\n5/158 [3]\n5/173 [3]\n73/215 [34]\n1/66 [2]\n\n\n   Korea\n8 (5,27-33)\n56/246 [23]\n21/223 [9]\n16/223 [7]\n93/246 [38]\n5/106 [5]\n\n\n   Malaysia\n1 (35)\n\n\n\n\n2/18 [11]\n\n\n   Taiwan\n1 (36)\n1/8 [13]\n1/8 [13]\n1/8 [13]\n3/8 [38]\n\n\n\n   Vietnam\n1 (10)\n4/23 [17]\n0/23 [0]\n0/23 [0]\n4/23 [17]\n\n\n\n   India\n1 (37)\n0/8 [0]\n0/8 [0]\n0/8 [0]\n0/8 [0]\n\n\n\n   Overall\n23\n134/553 [24]\n31/473 [7]\n25/488 [5]\n190/553 [34]\n9/243 [4]\n\n\nEurope\n\n\n\n\n\n\n\n\n   France\n4 (39-42)\n9/27 [33]\n0/11 [0]\n0/6 [0]\n9/32 [28]\n13/44 [30]\n\n\n   Germany\n3 (43-45)\n1/12 [8]\n0/12 [0]\n0/12 [0]\n1/12 [8]\n2/40 [5]\n\n\n   Italy\n7 (46-52)\n34/146 [23]\n8/120 [5]\n5/141 [4]\n47/146 [32]\n2/49 [4]\n\n\n   Portugal\n2 (53,54)\n2/25 [8]\n1/25 [4]\n0/25 [0]\n3/25 [12]\n13/41 [31]\n\n\n   Poland\n2 (55,56)\n2/55 [4]\n6/55 [11]\n2/55 [4]\n10/55 [18]\n0/20 [0]\n\n\n   UK\n2 (57,58)\n5/19 [26]\n3/19 [16]\n0/19 [0]\n8/19 [42]\n\n\n\n   Switzerland\n1 (15)\n\n\n\n\n5/31 [16]\n\n\n   Spain\n1 (59)\n2/10 [20]\n0/10 [0]\n0/10 [0]\n2/10 [20]\n\n\n\n   Turkey\n2 (60,61)\n\n\n0/13 [0]\n0/13 [0]\n3/9 [33]\n\n\n   Croatia\n1 (62)\n\n\n\n\n7/18 [39]\n\n\n   Denmark\n2 (63,64)\n3/24 [13]\n1/24 [4]\n0/24 [0]\n4/24 [17]\n7/44 [16]\n\n\n   Hungary\n1 (11)\n1/6 [17]\n2/6 [33]\n0/6 [0]\n3/6 [50]\n\n\n\n   Norway\n1 (65)\n2/7 [29]\n1/7 [14]\n\n3/7 [43]\n0/7 [0]\n\n\n   Sweden\n1 (66)\n\n\n\n\n10/34 [29]\n\n\n   Overall\n30\n61/331 [18]\n22/289 [8]\n7/311 [2]\n90/349 [26]\n62/337 [18]\n\n\nNorth America\n\n\n\n\n\n\n\n\n   USA\n15 (67-81)\n26/76 [34]\n4/76 [5]\n2/86 [2]\n57/194 [29]\n48/149 [32]\n\n\n   Canada\n1 (11)\n0/10 [0]\n1/10 [10]\n0/10 [0]\n1/10 [10]\n\n\n\n   Overall\n16\n26/86 [30]\n5/86 [6]\n2/96 [2]\n58/204 [28]\n48/149 [32]\n\n\nSouth America\n\n\n\n\n\n\n\n\n   Brazil\n1 (82)\n\n\n\n\n4/13 [31]\n\n\n   Overall\n1\n\n\n\n\n4/13 [31]\n\n\nOceania\n\n\n\n\n\n\n\n\n   Australia\n2 (83,84)\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\n   Overall\n2\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\nMiddle East\n\n\n\n\n\n\n\n\n   Saudi Arabia\n1 (38)\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n   Overall\n1\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n\nOpen in a new tab\nFTC, follicular thyroid carcinoma.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2B show the frequencies of PAX8/PPARγ rearrangement.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We used the remaining 71 studies that included data of at least one genetic alteration in our final analysis (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2A show the worldwide frequency of RAS mutation.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Country/region\nNo. studies\nNRAS\nHRAS\nKRAS\nAny RAS\nPAX8/PPARγ\n\nNo. with a mutation/total no. [%]\n\n\n\nAsia\n\n\n\n\n\n\n\n\n   China\n1 (34)\n10/53 [19]\n4/53 [8]\n3/53 [3]\n17/53 [32]\n1/53 [2]\n\n\n   Japan\n10 (6,10,16,17,21-26)\n63/215 [29]\n5/158 [3]\n5/173 [3]\n73/215 [34]\n1/66 [2]\n\n\n   Korea\n8 (5,27-33)\n56/246 [23]\n21/223 [9]\n16/223 [7]\n93/246 [38]\n5/106 [5]\n\n\n   Malaysia\n1 (35)\n\n\n\n\n2/18 [11]\n\n\n   Taiwan\n1 (36)\n1/8 [13]\n1/8 [13]\n1/8 [13]\n3/8 [38]\n\n\n\n   Vietnam\n1 (10)\n4/23 [17]\n0/23 [0]\n0/23 [0]\n4/23 [17]\n\n\n\n   India\n1 (37)\n0/8 [0]\n0/8 [0]\n0/8 [0]\n0/8 [0]\n\n\n\n   Overall\n23\n134/553 [24]\n31/473 [7]\n25/488 [5]\n190/553 [34]\n9/243 [4]\n\n\nEurope\n\n\n\n\n\n\n\n\n   France\n4 (39-42)\n9/27 [33]\n0/11 [0]\n0/6 [0]\n9/32 [28]\n13/44 [30]\n\n\n   Germany\n3 (43-45)\n1/12 [8]\n0/12 [0]\n0/12 [0]\n1/12 [8]\n2/40 [5]\n\n\n   Italy\n7 (46-52)\n34/146 [23]\n8/120 [5]\n5/141 [4]\n47/146 [32]\n2/49 [4]\n\n\n   Portugal\n2 (53,54)\n2/25 [8]\n1/25 [4]\n0/25 [0]\n3/25 [12]\n13/41 [31]\n\n\n   Poland\n2 (55,56)\n2/55 [4]\n6/55 [11]\n2/55 [4]\n10/55 [18]\n0/20 [0]\n\n\n   UK\n2 (57,58)\n5/19 [26]\n3/19 [16]\n0/19 [0]\n8/19 [42]\n\n\n\n   Switzerland\n1 (15)\n\n\n\n\n5/31 [16]\n\n\n   Spain\n1 (59)\n2/10 [20]\n0/10 [0]\n0/10 [0]\n2/10 [20]\n\n\n\n   Turkey\n2 (60,61)\n\n\n0/13 [0]\n0/13 [0]\n3/9 [33]\n\n\n   Croatia\n1 (62)\n\n\n\n\n7/18 [39]\n\n\n   Denmark\n2 (63,64)\n3/24 [13]\n1/24 [4]\n0/24 [0]\n4/24 [17]\n7/44 [16]\n\n\n   Hungary\n1 (11)\n1/6 [17]\n2/6 [33]\n0/6 [0]\n3/6 [50]\n\n\n\n   Norway\n1 (65)\n2/7 [29]\n1/7 [14]\n\n3/7 [43]\n0/7 [0]\n\n\n   Sweden\n1 (66)\n\n\n\n\n10/34 [29]\n\n\n   Overall\n30\n61/331 [18]\n22/289 [8]\n7/311 [2]\n90/349 [26]\n62/337 [18]\n\n\nNorth America\n\n\n\n\n\n\n\n\n   USA\n15 (67-81)\n26/76 [34]\n4/76 [5]\n2/86 [2]\n57/194 [29]\n48/149 [32]\n\n\n   Canada\n1 (11)\n0/10 [0]\n1/10 [10]\n0/10 [0]\n1/10 [10]\n\n\n\n   Overall\n16\n26/86 [30]\n5/86 [6]\n2/96 [2]\n58/204 [28]\n48/149 [32]\n\n\nSouth America\n\n\n\n\n\n\n\n\n   Brazil\n1 (82)\n\n\n\n\n4/13 [31]\n\n\n   Overall\n1\n\n\n\n\n4/13 [31]\n\n\nOceania\n\n\n\n\n\n\n\n\n   Australia\n2 (83,84)\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\n   Overall\n2\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\nMiddle East\n\n\n\n\n\n\n\n\n   Saudi Arabia\n1 (38)\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n   Overall\n1\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n\nOpen in a new tab\nFTC, follicular thyroid carcinoma.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2B show the frequencies of PAX8/PPARγ rearrangement.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We used the remaining 71 studies that included data of at least one genetic alteration in our final analysis (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2A show the worldwide frequency of RAS mutation.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Country/region\nNo. studies\nNRAS\nHRAS\nKRAS\nAny RAS\nPAX8/PPARγ\n\nNo. with a mutation/total no. [%]\n\n\n\nAsia\n\n\n\n\n\n\n\n\n   China\n1 (34)\n10/53 [19]\n4/53 [8]\n3/53 [3]\n17/53 [32]\n1/53 [2]\n\n\n   Japan\n10 (6,10,16,17,21-26)\n63/215 [29]\n5/158 [3]\n5/173 [3]\n73/215 [34]\n1/66 [2]\n\n\n   Korea\n8 (5,27-33)\n56/246 [23]\n21/223 [9]\n16/223 [7]\n93/246 [38]\n5/106 [5]\n\n\n   Malaysia\n1 (35)\n\n\n\n\n2/18 [11]\n\n\n   Taiwan\n1 (36)\n1/8 [13]\n1/8 [13]\n1/8 [13]\n3/8 [38]\n\n\n\n   Vietnam\n1 (10)\n4/23 [17]\n0/23 [0]\n0/23 [0]\n4/23 [17]\n\n\n\n   India\n1 (37)\n0/8 [0]\n0/8 [0]\n0/8 [0]\n0/8 [0]\n\n\n\n   Overall\n23\n134/553 [24]\n31/473 [7]\n25/488 [5]\n190/553 [34]\n9/243 [4]\n\n\nEurope\n\n\n\n\n\n\n\n\n   France\n4 (39-42)\n9/27 [33]\n0/11 [0]\n0/6 [0]\n9/32 [28]\n13/44 [30]\n\n\n   Germany\n3 (43-45)\n1/12 [8]\n0/12 [0]\n0/12 [0]\n1/12 [8]\n2/40 [5]\n\n\n   Italy\n7 (46-52)\n34/146 [23]\n8/120 [5]\n5/141 [4]\n47/146 [32]\n2/49 [4]\n\n\n   Portugal\n2 (53,54)\n2/25 [8]\n1/25 [4]\n0/25 [0]\n3/25 [12]\n13/41 [31]\n\n\n   Poland\n2 (55,56)\n2/55 [4]\n6/55 [11]\n2/55 [4]\n10/55 [18]\n0/20 [0]\n\n\n   UK\n2 (57,58)\n5/19 [26]\n3/19 [16]\n0/19 [0]\n8/19 [42]\n\n\n\n   Switzerland\n1 (15)\n\n\n\n\n5/31 [16]\n\n\n   Spain\n1 (59)\n2/10 [20]\n0/10 [0]\n0/10 [0]\n2/10 [20]\n\n\n\n   Turkey\n2 (60,61)\n\n\n0/13 [0]\n0/13 [0]\n3/9 [33]\n\n\n   Croatia\n1 (62)\n\n\n\n\n7/18 [39]\n\n\n   Denmark\n2 (63,64)\n3/24 [13]\n1/24 [4]\n0/24 [0]\n4/24 [17]\n7/44 [16]\n\n\n   Hungary\n1 (11)\n1/6 [17]\n2/6 [33]\n0/6 [0]\n3/6 [50]\n\n\n\n   Norway\n1 (65)\n2/7 [29]\n1/7 [14]\n\n3/7 [43]\n0/7 [0]\n\n\n   Sweden\n1 (66)\n\n\n\n\n10/34 [29]\n\n\n   Overall\n30\n61/331 [18]\n22/289 [8]\n7/311 [2]\n90/349 [26]\n62/337 [18]\n\n\nNorth America\n\n\n\n\n\n\n\n\n   USA\n15 (67-81)\n26/76 [34]\n4/76 [5]\n2/86 [2]\n57/194 [29]\n48/149 [32]\n\n\n   Canada\n1 (11)\n0/10 [0]\n1/10 [10]\n0/10 [0]\n1/10 [10]\n\n\n\n   Overall\n16\n26/86 [30]\n5/86 [6]\n2/96 [2]\n58/204 [28]\n48/149 [32]\n\n\nSouth America\n\n\n\n\n\n\n\n\n   Brazil\n1 (82)\n\n\n\n\n4/13 [31]\n\n\n   Overall\n1\n\n\n\n\n4/13 [31]\n\n\nOceania\n\n\n\n\n\n\n\n\n   Australia\n2 (83,84)\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\n   Overall\n2\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\nMiddle East\n\n\n\n\n\n\n\n\n   Saudi Arabia\n1 (38)\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n   Overall\n1\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n\nOpen in a new tab\nFTC, follicular thyroid carcinoma.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2B show the frequencies of PAX8/PPARγ rearrangement.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We used the remaining 71 studies that included data of at least one genetic alteration in our final analysis (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2A show the worldwide frequency of RAS mutation.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Country/region\nNo. studies\nNRAS\nHRAS\nKRAS\nAny RAS\nPAX8/PPARγ\n\nNo. with a mutation/total no. [%]\n\n\n\nAsia\n\n\n\n\n\n\n\n\n   China\n1 (34)\n10/53 [19]\n4/53 [8]\n3/53 [3]\n17/53 [32]\n1/53 [2]\n\n\n   Japan\n10 (6,10,16,17,21-26)\n63/215 [29]\n5/158 [3]\n5/173 [3]\n73/215 [34]\n1/66 [2]\n\n\n   Korea\n8 (5,27-33)\n56/246 [23]\n21/223 [9]\n16/223 [7]\n93/246 [38]\n5/106 [5]\n\n\n   Malaysia\n1 (35)\n\n\n\n\n2/18 [11]\n\n\n   Taiwan\n1 (36)\n1/8 [13]\n1/8 [13]\n1/8 [13]\n3/8 [38]\n\n\n\n   Vietnam\n1 (10)\n4/23 [17]\n0/23 [0]\n0/23 [0]\n4/23 [17]\n\n\n\n   India\n1 (37)\n0/8 [0]\n0/8 [0]\n0/8 [0]\n0/8 [0]\n\n\n\n   Overall\n23\n134/553 [24]\n31/473 [7]\n25/488 [5]\n190/553 [34]\n9/243 [4]\n\n\nEurope\n\n\n\n\n\n\n\n\n   France\n4 (39-42)\n9/27 [33]\n0/11 [0]\n0/6 [0]\n9/32 [28]\n13/44 [30]\n\n\n   Germany\n3 (43-45)\n1/12 [8]\n0/12 [0]\n0/12 [0]\n1/12 [8]\n2/40 [5]\n\n\n   Italy\n7 (46-52)\n34/146 [23]\n8/120 [5]\n5/141 [4]\n47/146 [32]\n2/49 [4]\n\n\n   Portugal\n2 (53,54)\n2/25 [8]\n1/25 [4]\n0/25 [0]\n3/25 [12]\n13/41 [31]\n\n\n   Poland\n2 (55,56)\n2/55 [4]\n6/55 [11]\n2/55 [4]\n10/55 [18]\n0/20 [0]\n\n\n   UK\n2 (57,58)\n5/19 [26]\n3/19 [16]\n0/19 [0]\n8/19 [42]\n\n\n\n   Switzerland\n1 (15)\n\n\n\n\n5/31 [16]\n\n\n   Spain\n1 (59)\n2/10 [20]\n0/10 [0]\n0/10 [0]\n2/10 [20]\n\n\n\n   Turkey\n2 (60,61)\n\n\n0/13 [0]\n0/13 [0]\n3/9 [33]\n\n\n   Croatia\n1 (62)\n\n\n\n\n7/18 [39]\n\n\n   Denmark\n2 (63,64)\n3/24 [13]\n1/24 [4]\n0/24 [0]\n4/24 [17]\n7/44 [16]\n\n\n   Hungary\n1 (11)\n1/6 [17]\n2/6 [33]\n0/6 [0]\n3/6 [50]\n\n\n\n   Norway\n1 (65)\n2/7 [29]\n1/7 [14]\n\n3/7 [43]\n0/7 [0]\n\n\n   Sweden\n1 (66)\n\n\n\n\n10/34 [29]\n\n\n   Overall\n30\n61/331 [18]\n22/289 [8]\n7/311 [2]\n90/349 [26]\n62/337 [18]\n\n\nNorth America\n\n\n\n\n\n\n\n\n   USA\n15 (67-81)\n26/76 [34]\n4/76 [5]\n2/86 [2]\n57/194 [29]\n48/149 [32]\n\n\n   Canada\n1 (11)\n0/10 [0]\n1/10 [10]\n0/10 [0]\n1/10 [10]\n\n\n\n   Overall\n16\n26/86 [30]\n5/86 [6]\n2/96 [2]\n58/204 [28]\n48/149 [32]\n\n\nSouth America\n\n\n\n\n\n\n\n\n   Brazil\n1 (82)\n\n\n\n\n4/13 [31]\n\n\n   Overall\n1\n\n\n\n\n4/13 [31]\n\n\nOceania\n\n\n\n\n\n\n\n\n   Australia\n2 (83,84)\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\n   Overall\n2\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\nMiddle East\n\n\n\n\n\n\n\n\n   Saudi Arabia\n1 (38)\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n   Overall\n1\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n\nOpen in a new tab\nFTC, follicular thyroid carcinoma.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2B show the frequencies of PAX8/PPARγ rearrangement.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We used the remaining 71 studies that included data of at least one genetic alteration in our final analysis (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2A show the worldwide frequency of RAS mutation.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Country/region\nNo. studies\nNRAS\nHRAS\nKRAS\nAny RAS\nPAX8/PPARγ\n\nNo. with a mutation/total no. [%]\n\n\n\nAsia\n\n\n\n\n\n\n\n\n   China\n1 (34)\n10/53 [19]\n4/53 [8]\n3/53 [3]\n17/53 [32]\n1/53 [2]\n\n\n   Japan\n10 (6,10,16,17,21-26)\n63/215 [29]\n5/158 [3]\n5/173 [3]\n73/215 [34]\n1/66 [2]\n\n\n   Korea\n8 (5,27-33)\n56/246 [23]\n21/223 [9]\n16/223 [7]\n93/246 [38]\n5/106 [5]\n\n\n   Malaysia\n1 (35)\n\n\n\n\n2/18 [11]\n\n\n   Taiwan\n1 (36)\n1/8 [13]\n1/8 [13]\n1/8 [13]\n3/8 [38]\n\n\n\n   Vietnam\n1 (10)\n4/23 [17]\n0/23 [0]\n0/23 [0]\n4/23 [17]\n\n\n\n   India\n1 (37)\n0/8 [0]\n0/8 [0]\n0/8 [0]\n0/8 [0]\n\n\n\n   Overall\n23\n134/553 [24]\n31/473 [7]\n25/488 [5]\n190/553 [34]\n9/243 [4]\n\n\nEurope\n\n\n\n\n\n\n\n\n   France\n4 (39-42)\n9/27 [33]\n0/11 [0]\n0/6 [0]\n9/32 [28]\n13/44 [30]\n\n\n   Germany\n3 (43-45)\n1/12 [8]\n0/12 [0]\n0/12 [0]\n1/12 [8]\n2/40 [5]\n\n\n   Italy\n7 (46-52)\n34/146 [23]\n8/120 [5]\n5/141 [4]\n47/146 [32]\n2/49 [4]\n\n\n   Portugal\n2 (53,54)\n2/25 [8]\n1/25 [4]\n0/25 [0]\n3/25 [12]\n13/41 [31]\n\n\n   Poland\n2 (55,56)\n2/55 [4]\n6/55 [11]\n2/55 [4]\n10/55 [18]\n0/20 [0]\n\n\n   UK\n2 (57,58)\n5/19 [26]\n3/19 [16]\n0/19 [0]\n8/19 [42]\n\n\n\n   Switzerland\n1 (15)\n\n\n\n\n5/31 [16]\n\n\n   Spain\n1 (59)\n2/10 [20]\n0/10 [0]\n0/10 [0]\n2/10 [20]\n\n\n\n   Turkey\n2 (60,61)\n\n\n0/13 [0]\n0/13 [0]\n3/9 [33]\n\n\n   Croatia\n1 (62)\n\n\n\n\n7/18 [39]\n\n\n   Denmark\n2 (63,64)\n3/24 [13]\n1/24 [4]\n0/24 [0]\n4/24 [17]\n7/44 [16]\n\n\n   Hungary\n1 (11)\n1/6 [17]\n2/6 [33]\n0/6 [0]\n3/6 [50]\n\n\n\n   Norway\n1 (65)\n2/7 [29]\n1/7 [14]\n\n3/7 [43]\n0/7 [0]\n\n\n   Sweden\n1 (66)\n\n\n\n\n10/34 [29]\n\n\n   Overall\n30\n61/331 [18]\n22/289 [8]\n7/311 [2]\n90/349 [26]\n62/337 [18]\n\n\nNorth America\n\n\n\n\n\n\n\n\n   USA\n15 (67-81)\n26/76 [34]\n4/76 [5]\n2/86 [2]\n57/194 [29]\n48/149 [32]\n\n\n   Canada\n1 (11)\n0/10 [0]\n1/10 [10]\n0/10 [0]\n1/10 [10]\n\n\n\n   Overall\n16\n26/86 [30]\n5/86 [6]\n2/96 [2]\n58/204 [28]\n48/149 [32]\n\n\nSouth America\n\n\n\n\n\n\n\n\n   Brazil\n1 (82)\n\n\n\n\n4/13 [31]\n\n\n   Overall\n1\n\n\n\n\n4/13 [31]\n\n\nOceania\n\n\n\n\n\n\n\n\n   Australia\n2 (83,84)\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\n   Overall\n2\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\nMiddle East\n\n\n\n\n\n\n\n\n   Saudi Arabia\n1 (38)\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n   Overall\n1\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n\nOpen in a new tab\nFTC, follicular thyroid carcinoma.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2B show the frequencies of PAX8/PPARγ rearrangement.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We used the remaining 71 studies that included data of at least one genetic alteration in our final analysis (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2A show the worldwide frequency of RAS mutation.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Country/region\nNo. studies\nNRAS\nHRAS\nKRAS\nAny RAS\nPAX8/PPARγ\n\nNo. with a mutation/total no. [%]\n\n\n\nAsia\n\n\n\n\n\n\n\n\n   China\n1 (34)\n10/53 [19]\n4/53 [8]\n3/53 [3]\n17/53 [32]\n1/53 [2]\n\n\n   Japan\n10 (6,10,16,17,21-26)\n63/215 [29]\n5/158 [3]\n5/173 [3]\n73/215 [34]\n1/66 [2]\n\n\n   Korea\n8 (5,27-33)\n56/246 [23]\n21/223 [9]\n16/223 [7]\n93/246 [38]\n5/106 [5]\n\n\n   Malaysia\n1 (35)\n\n\n\n\n2/18 [11]\n\n\n   Taiwan\n1 (36)\n1/8 [13]\n1/8 [13]\n1/8 [13]\n3/8 [38]\n\n\n\n   Vietnam\n1 (10)\n4/23 [17]\n0/23 [0]\n0/23 [0]\n4/23 [17]\n\n\n\n   India\n1 (37)\n0/8 [0]\n0/8 [0]\n0/8 [0]\n0/8 [0]\n\n\n\n   Overall\n23\n134/553 [24]\n31/473 [7]\n25/488 [5]\n190/553 [34]\n9/243 [4]\n\n\nEurope\n\n\n\n\n\n\n\n\n   France\n4 (39-42)\n9/27 [33]\n0/11 [0]\n0/6 [0]\n9/32 [28]\n13/44 [30]\n\n\n   Germany\n3 (43-45)\n1/12 [8]\n0/12 [0]\n0/12 [0]\n1/12 [8]\n2/40 [5]\n\n\n   Italy\n7 (46-52)\n34/146 [23]\n8/120 [5]\n5/141 [4]\n47/146 [32]\n2/49 [4]\n\n\n   Portugal\n2 (53,54)\n2/25 [8]\n1/25 [4]\n0/25 [0]\n3/25 [12]\n13/41 [31]\n\n\n   Poland\n2 (55,56)\n2/55 [4]\n6/55 [11]\n2/55 [4]\n10/55 [18]\n0/20 [0]\n\n\n   UK\n2 (57,58)\n5/19 [26]\n3/19 [16]\n0/19 [0]\n8/19 [42]\n\n\n\n   Switzerland\n1 (15)\n\n\n\n\n5/31 [16]\n\n\n   Spain\n1 (59)\n2/10 [20]\n0/10 [0]\n0/10 [0]\n2/10 [20]\n\n\n\n   Turkey\n2 (60,61)\n\n\n0/13 [0]\n0/13 [0]\n3/9 [33]\n\n\n   Croatia\n1 (62)\n\n\n\n\n7/18 [39]\n\n\n   Denmark\n2 (63,64)\n3/24 [13]\n1/24 [4]\n0/24 [0]\n4/24 [17]\n7/44 [16]\n\n\n   Hungary\n1 (11)\n1/6 [17]\n2/6 [33]\n0/6 [0]\n3/6 [50]\n\n\n\n   Norway\n1 (65)\n2/7 [29]\n1/7 [14]\n\n3/7 [43]\n0/7 [0]\n\n\n   Sweden\n1 (66)\n\n\n\n\n10/34 [29]\n\n\n   Overall\n30\n61/331 [18]\n22/289 [8]\n7/311 [2]\n90/349 [26]\n62/337 [18]\n\n\nNorth America\n\n\n\n\n\n\n\n\n   USA\n15 (67-81)\n26/76 [34]\n4/76 [5]\n2/86 [2]\n57/194 [29]\n48/149 [32]\n\n\n   Canada\n1 (11)\n0/10 [0]\n1/10 [10]\n0/10 [0]\n1/10 [10]\n\n\n\n   Overall\n16\n26/86 [30]\n5/86 [6]\n2/96 [2]\n58/204 [28]\n48/149 [32]\n\n\nSouth America\n\n\n\n\n\n\n\n\n   Brazil\n1 (82)\n\n\n\n\n4/13 [31]\n\n\n   Overall\n1\n\n\n\n\n4/13 [31]\n\n\nOceania\n\n\n\n\n\n\n\n\n   Australia\n2 (83,84)\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\n   Overall\n2\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\nMiddle East\n\n\n\n\n\n\n\n\n   Saudi Arabia\n1 (38)\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n   Overall\n1\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n\nOpen in a new tab\nFTC, follicular thyroid carcinoma.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2B show the frequencies of PAX8/PPARγ rearrangement.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We used the remaining 71 studies that included data of at least one genetic alteration in our final analysis (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2A show the worldwide frequency of RAS mutation.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Country/region\nNo. studies\nNRAS\nHRAS\nKRAS\nAny RAS\nPAX8/PPARγ\n\nNo. with a mutation/total no. [%]\n\n\n\nAsia\n\n\n\n\n\n\n\n\n   China\n1 (34)\n10/53 [19]\n4/53 [8]\n3/53 [3]\n17/53 [32]\n1/53 [2]\n\n\n   Japan\n10 (6,10,16,17,21-26)\n63/215 [29]\n5/158 [3]\n5/173 [3]\n73/215 [34]\n1/66 [2]\n\n\n   Korea\n8 (5,27-33)\n56/246 [23]\n21/223 [9]\n16/223 [7]\n93/246 [38]\n5/106 [5]\n\n\n   Malaysia\n1 (35)\n\n\n\n\n2/18 [11]\n\n\n   Taiwan\n1 (36)\n1/8 [13]\n1/8 [13]\n1/8 [13]\n3/8 [38]\n\n\n\n   Vietnam\n1 (10)\n4/23 [17]\n0/23 [0]\n0/23 [0]\n4/23 [17]\n\n\n\n   India\n1 (37)\n0/8 [0]\n0/8 [0]\n0/8 [0]\n0/8 [0]\n\n\n\n   Overall\n23\n134/553 [24]\n31/473 [7]\n25/488 [5]\n190/553 [34]\n9/243 [4]\n\n\nEurope\n\n\n\n\n\n\n\n\n   France\n4 (39-42)\n9/27 [33]\n0/11 [0]\n0/6 [0]\n9/32 [28]\n13/44 [30]\n\n\n   Germany\n3 (43-45)\n1/12 [8]\n0/12 [0]\n0/12 [0]\n1/12 [8]\n2/40 [5]\n\n\n   Italy\n7 (46-52)\n34/146 [23]\n8/120 [5]\n5/141 [4]\n47/146 [32]\n2/49 [4]\n\n\n   Portugal\n2 (53,54)\n2/25 [8]\n1/25 [4]\n0/25 [0]\n3/25 [12]\n13/41 [31]\n\n\n   Poland\n2 (55,56)\n2/55 [4]\n6/55 [11]\n2/55 [4]\n10/55 [18]\n0/20 [0]\n\n\n   UK\n2 (57,58)\n5/19 [26]\n3/19 [16]\n0/19 [0]\n8/19 [42]\n\n\n\n   Switzerland\n1 (15)\n\n\n\n\n5/31 [16]\n\n\n   Spain\n1 (59)\n2/10 [20]\n0/10 [0]\n0/10 [0]\n2/10 [20]\n\n\n\n   Turkey\n2 (60,61)\n\n\n0/13 [0]\n0/13 [0]\n3/9 [33]\n\n\n   Croatia\n1 (62)\n\n\n\n\n7/18 [39]\n\n\n   Denmark\n2 (63,64)\n3/24 [13]\n1/24 [4]\n0/24 [0]\n4/24 [17]\n7/44 [16]\n\n\n   Hungary\n1 (11)\n1/6 [17]\n2/6 [33]\n0/6 [0]\n3/6 [50]\n\n\n\n   Norway\n1 (65)\n2/7 [29]\n1/7 [14]\n\n3/7 [43]\n0/7 [0]\n\n\n   Sweden\n1 (66)\n\n\n\n\n10/34 [29]\n\n\n   Overall\n30\n61/331 [18]\n22/289 [8]\n7/311 [2]\n90/349 [26]\n62/337 [18]\n\n\nNorth America\n\n\n\n\n\n\n\n\n   USA\n15 (67-81)\n26/76 [34]\n4/76 [5]\n2/86 [2]\n57/194 [29]\n48/149 [32]\n\n\n   Canada\n1 (11)\n0/10 [0]\n1/10 [10]\n0/10 [0]\n1/10 [10]\n\n\n\n   Overall\n16\n26/86 [30]\n5/86 [6]\n2/96 [2]\n58/204 [28]\n48/149 [32]\n\n\nSouth America\n\n\n\n\n\n\n\n\n   Brazil\n1 (82)\n\n\n\n\n4/13 [31]\n\n\n   Overall\n1\n\n\n\n\n4/13 [31]\n\n\nOceania\n\n\n\n\n\n\n\n\n   Australia\n2 (83,84)\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\n   Overall\n2\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\nMiddle East\n\n\n\n\n\n\n\n\n   Saudi Arabia\n1 (38)\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n   Overall\n1\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n\nOpen in a new tab\nFTC, follicular thyroid carcinoma.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2B show the frequencies of PAX8/PPARγ rearrangement.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We used the remaining 71 studies that included data of at least one genetic alteration in our final analysis (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2A show the worldwide frequency of RAS mutation.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Country/region\nNo. studies\nNRAS\nHRAS\nKRAS\nAny RAS\nPAX8/PPARγ\n\nNo. with a mutation/total no. [%]\n\n\n\nAsia\n\n\n\n\n\n\n\n\n   China\n1 (34)\n10/53 [19]\n4/53 [8]\n3/53 [3]\n17/53 [32]\n1/53 [2]\n\n\n   Japan\n10 (6,10,16,17,21-26)\n63/215 [29]\n5/158 [3]\n5/173 [3]\n73/215 [34]\n1/66 [2]\n\n\n   Korea\n8 (5,27-33)\n56/246 [23]\n21/223 [9]\n16/223 [7]\n93/246 [38]\n5/106 [5]\n\n\n   Malaysia\n1 (35)\n\n\n\n\n2/18 [11]\n\n\n   Taiwan\n1 (36)\n1/8 [13]\n1/8 [13]\n1/8 [13]\n3/8 [38]\n\n\n\n   Vietnam\n1 (10)\n4/23 [17]\n0/23 [0]\n0/23 [0]\n4/23 [17]\n\n\n\n   India\n1 (37)\n0/8 [0]\n0/8 [0]\n0/8 [0]\n0/8 [0]\n\n\n\n   Overall\n23\n134/553 [24]\n31/473 [7]\n25/488 [5]\n190/553 [34]\n9/243 [4]\n\n\nEurope\n\n\n\n\n\n\n\n\n   France\n4 (39-42)\n9/27 [33]\n0/11 [0]\n0/6 [0]\n9/32 [28]\n13/44 [30]\n\n\n   Germany\n3 (43-45)\n1/12 [8]\n0/12 [0]\n0/12 [0]\n1/12 [8]\n2/40 [5]\n\n\n   Italy\n7 (46-52)\n34/146 [23]\n8/120 [5]\n5/141 [4]\n47/146 [32]\n2/49 [4]\n\n\n   Portugal\n2 (53,54)\n2/25 [8]\n1/25 [4]\n0/25 [0]\n3/25 [12]\n13/41 [31]\n\n\n   Poland\n2 (55,56)\n2/55 [4]\n6/55 [11]\n2/55 [4]\n10/55 [18]\n0/20 [0]\n\n\n   UK\n2 (57,58)\n5/19 [26]\n3/19 [16]\n0/19 [0]\n8/19 [42]\n\n\n\n   Switzerland\n1 (15)\n\n\n\n\n5/31 [16]\n\n\n   Spain\n1 (59)\n2/10 [20]\n0/10 [0]\n0/10 [0]\n2/10 [20]\n\n\n\n   Turkey\n2 (60,61)\n\n\n0/13 [0]\n0/13 [0]\n3/9 [33]\n\n\n   Croatia\n1 (62)\n\n\n\n\n7/18 [39]\n\n\n   Denmark\n2 (63,64)\n3/24 [13]\n1/24 [4]\n0/24 [0]\n4/24 [17]\n7/44 [16]\n\n\n   Hungary\n1 (11)\n1/6 [17]\n2/6 [33]\n0/6 [0]\n3/6 [50]\n\n\n\n   Norway\n1 (65)\n2/7 [29]\n1/7 [14]\n\n3/7 [43]\n0/7 [0]\n\n\n   Sweden\n1 (66)\n\n\n\n\n10/34 [29]\n\n\n   Overall\n30\n61/331 [18]\n22/289 [8]\n7/311 [2]\n90/349 [26]\n62/337 [18]\n\n\nNorth America\n\n\n\n\n\n\n\n\n   USA\n15 (67-81)\n26/76 [34]\n4/76 [5]\n2/86 [2]\n57/194 [29]\n48/149 [32]\n\n\n   Canada\n1 (11)\n0/10 [0]\n1/10 [10]\n0/10 [0]\n1/10 [10]\n\n\n\n   Overall\n16\n26/86 [30]\n5/86 [6]\n2/96 [2]\n58/204 [28]\n48/149 [32]\n\n\nSouth America\n\n\n\n\n\n\n\n\n   Brazil\n1 (82)\n\n\n\n\n4/13 [31]\n\n\n   Overall\n1\n\n\n\n\n4/13 [31]\n\n\nOceania\n\n\n\n\n\n\n\n\n   Australia\n2 (83,84)\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\n   Overall\n2\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\nMiddle East\n\n\n\n\n\n\n\n\n   Saudi Arabia\n1 (38)\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n   Overall\n1\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n\nOpen in a new tab\nFTC, follicular thyroid carcinoma.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2B show the frequencies of PAX8/PPARγ rearrangement.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We used the remaining 71 studies that included data of at least one genetic alteration in our final analysis (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2A show the worldwide frequency of RAS mutation.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Country/region\nNo. studies\nNRAS\nHRAS\nKRAS\nAny RAS\nPAX8/PPARγ\n\nNo. with a mutation/total no. [%]\n\n\n\nAsia\n\n\n\n\n\n\n\n\n   China\n1 (34)\n10/53 [19]\n4/53 [8]\n3/53 [3]\n17/53 [32]\n1/53 [2]\n\n\n   Japan\n10 (6,10,16,17,21-26)\n63/215 [29]\n5/158 [3]\n5/173 [3]\n73/215 [34]\n1/66 [2]\n\n\n   Korea\n8 (5,27-33)\n56/246 [23]\n21/223 [9]\n16/223 [7]\n93/246 [38]\n5/106 [5]\n\n\n   Malaysia\n1 (35)\n\n\n\n\n2/18 [11]\n\n\n   Taiwan\n1 (36)\n1/8 [13]\n1/8 [13]\n1/8 [13]\n3/8 [38]\n\n\n\n   Vietnam\n1 (10)\n4/23 [17]\n0/23 [0]\n0/23 [0]\n4/23 [17]\n\n\n\n   India\n1 (37)\n0/8 [0]\n0/8 [0]\n0/8 [0]\n0/8 [0]\n\n\n\n   Overall\n23\n134/553 [24]\n31/473 [7]\n25/488 [5]\n190/553 [34]\n9/243 [4]\n\n\nEurope\n\n\n\n\n\n\n\n\n   France\n4 (39-42)\n9/27 [33]\n0/11 [0]\n0/6 [0]\n9/32 [28]\n13/44 [30]\n\n\n   Germany\n3 (43-45)\n1/12 [8]\n0/12 [0]\n0/12 [0]\n1/12 [8]\n2/40 [5]\n\n\n   Italy\n7 (46-52)\n34/146 [23]\n8/120 [5]\n5/141 [4]\n47/146 [32]\n2/49 [4]\n\n\n   Portugal\n2 (53,54)\n2/25 [8]\n1/25 [4]\n0/25 [0]\n3/25 [12]\n13/41 [31]\n\n\n   Poland\n2 (55,56)\n2/55 [4]\n6/55 [11]\n2/55 [4]\n10/55 [18]\n0/20 [0]\n\n\n   UK\n2 (57,58)\n5/19 [26]\n3/19 [16]\n0/19 [0]\n8/19 [42]\n\n\n\n   Switzerland\n1 (15)\n\n\n\n\n5/31 [16]\n\n\n   Spain\n1 (59)\n2/10 [20]\n0/10 [0]\n0/10 [0]\n2/10 [20]\n\n\n\n   Turkey\n2 (60,61)\n\n\n0/13 [0]\n0/13 [0]\n3/9 [33]\n\n\n   Croatia\n1 (62)\n\n\n\n\n7/18 [39]\n\n\n   Denmark\n2 (63,64)\n3/24 [13]\n1/24 [4]\n0/24 [0]\n4/24 [17]\n7/44 [16]\n\n\n   Hungary\n1 (11)\n1/6 [17]\n2/6 [33]\n0/6 [0]\n3/6 [50]\n\n\n\n   Norway\n1 (65)\n2/7 [29]\n1/7 [14]\n\n3/7 [43]\n0/7 [0]\n\n\n   Sweden\n1 (66)\n\n\n\n\n10/34 [29]\n\n\n   Overall\n30\n61/331 [18]\n22/289 [8]\n7/311 [2]\n90/349 [26]\n62/337 [18]\n\n\nNorth America\n\n\n\n\n\n\n\n\n   USA\n15 (67-81)\n26/76 [34]\n4/76 [5]\n2/86 [2]\n57/194 [29]\n48/149 [32]\n\n\n   Canada\n1 (11)\n0/10 [0]\n1/10 [10]\n0/10 [0]\n1/10 [10]\n\n\n\n   Overall\n16\n26/86 [30]\n5/86 [6]\n2/96 [2]\n58/204 [28]\n48/149 [32]\n\n\nSouth America\n\n\n\n\n\n\n\n\n   Brazil\n1 (82)\n\n\n\n\n4/13 [31]\n\n\n   Overall\n1\n\n\n\n\n4/13 [31]\n\n\nOceania\n\n\n\n\n\n\n\n\n   Australia\n2 (83,84)\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\n   Overall\n2\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\nMiddle East\n\n\n\n\n\n\n\n\n   Saudi Arabia\n1 (38)\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n   Overall\n1\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n\nOpen in a new tab\nFTC, follicular thyroid carcinoma.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2B show the frequencies of PAX8/PPARγ rearrangement.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We used the remaining 71 studies that included data of at least one genetic alteration in our final analysis (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2A show the worldwide frequency of RAS mutation.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Country/region\nNo. studies\nNRAS\nHRAS\nKRAS\nAny RAS\nPAX8/PPARγ\n\nNo. with a mutation/total no. [%]\n\n\n\nAsia\n\n\n\n\n\n\n\n\n   China\n1 (34)\n10/53 [19]\n4/53 [8]\n3/53 [3]\n17/53 [32]\n1/53 [2]\n\n\n   Japan\n10 (6,10,16,17,21-26)\n63/215 [29]\n5/158 [3]\n5/173 [3]\n73/215 [34]\n1/66 [2]\n\n\n   Korea\n8 (5,27-33)\n56/246 [23]\n21/223 [9]\n16/223 [7]\n93/246 [38]\n5/106 [5]\n\n\n   Malaysia\n1 (35)\n\n\n\n\n2/18 [11]\n\n\n   Taiwan\n1 (36)\n1/8 [13]\n1/8 [13]\n1/8 [13]\n3/8 [38]\n\n\n\n   Vietnam\n1 (10)\n4/23 [17]\n0/23 [0]\n0/23 [0]\n4/23 [17]\n\n\n\n   India\n1 (37)\n0/8 [0]\n0/8 [0]\n0/8 [0]\n0/8 [0]\n\n\n\n   Overall\n23\n134/553 [24]\n31/473 [7]\n25/488 [5]\n190/553 [34]\n9/243 [4]\n\n\nEurope\n\n\n\n\n\n\n\n\n   France\n4 (39-42)\n9/27 [33]\n0/11 [0]\n0/6 [0]\n9/32 [28]\n13/44 [30]\n\n\n   Germany\n3 (43-45)\n1/12 [8]\n0/12 [0]\n0/12 [0]\n1/12 [8]\n2/40 [5]\n\n\n   Italy\n7 (46-52)\n34/146 [23]\n8/120 [5]\n5/141 [4]\n47/146 [32]\n2/49 [4]\n\n\n   Portugal\n2 (53,54)\n2/25 [8]\n1/25 [4]\n0/25 [0]\n3/25 [12]\n13/41 [31]\n\n\n   Poland\n2 (55,56)\n2/55 [4]\n6/55 [11]\n2/55 [4]\n10/55 [18]\n0/20 [0]\n\n\n   UK\n2 (57,58)\n5/19 [26]\n3/19 [16]\n0/19 [0]\n8/19 [42]\n\n\n\n   Switzerland\n1 (15)\n\n\n\n\n5/31 [16]\n\n\n   Spain\n1 (59)\n2/10 [20]\n0/10 [0]\n0/10 [0]\n2/10 [20]\n\n\n\n   Turkey\n2 (60,61)\n\n\n0/13 [0]\n0/13 [0]\n3/9 [33]\n\n\n   Croatia\n1 (62)\n\n\n\n\n7/18 [39]\n\n\n   Denmark\n2 (63,64)\n3/24 [13]\n1/24 [4]\n0/24 [0]\n4/24 [17]\n7/44 [16]\n\n\n   Hungary\n1 (11)\n1/6 [17]\n2/6 [33]\n0/6 [0]\n3/6 [50]\n\n\n\n   Norway\n1 (65)\n2/7 [29]\n1/7 [14]\n\n3/7 [43]\n0/7 [0]\n\n\n   Sweden\n1 (66)\n\n\n\n\n10/34 [29]\n\n\n   Overall\n30\n61/331 [18]\n22/289 [8]\n7/311 [2]\n90/349 [26]\n62/337 [18]\n\n\nNorth America\n\n\n\n\n\n\n\n\n   USA\n15 (67-81)\n26/76 [34]\n4/76 [5]\n2/86 [2]\n57/194 [29]\n48/149 [32]\n\n\n   Canada\n1 (11)\n0/10 [0]\n1/10 [10]\n0/10 [0]\n1/10 [10]\n\n\n\n   Overall\n16\n26/86 [30]\n5/86 [6]\n2/96 [2]\n58/204 [28]\n48/149 [32]\n\n\nSouth America\n\n\n\n\n\n\n\n\n   Brazil\n1 (82)\n\n\n\n\n4/13 [31]\n\n\n   Overall\n1\n\n\n\n\n4/13 [31]\n\n\nOceania\n\n\n\n\n\n\n\n\n   Australia\n2 (83,84)\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\n   Overall\n2\n5/27 [19]\n3/27 [11]\n0/27 [0]\n8/27 [30]\n7/22 [32]\n\n\nMiddle East\n\n\n\n\n\n\n\n\n   Saudi Arabia\n1 (38)\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n   Overall\n1\n1/10 [10]\n1/10 [10]\n0/10 [0]\n2/10 [20]\n\n\n\n\nOpen in a new tab\nFTC, follicular thyroid carcinoma.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2A show the worldwide frequency of RAS mutation.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2B show the frequencies of PAX8/PPARγ rearrangement.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Table 2 and Figure 2B show the frequencies of PAX8/PPARγ rearrangement.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 2,
    "claims_count": 42,
    "images_downloaded": 2,
    "tables_filtered": 261
  }
}